ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1518

Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test

JoAnn Ball1, Kelsy Greenwald1, Atul A. Deodhar2 and Kevin L. Winthrop3, 1Rheumatology, Desert Medical Advances, Palm Desert, CA, 2Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 3Oregon Health and Sciences University, Portland, OR

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologic drugs, Diagnostic Tests, interferons, rheumatoid arthritis (RA) and tuberculosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP).  BiP in both serum and synovial fluid is over-expressed in RA patients and correlates with CCP1. Serum BiP causes T cell expansion and increases interferon during incubation of the QuantiFERON-Gold tuberculosis in-tube test (QFT-G TB) which can result in a false positive TB test. The QFT-G TB has never been validated where interferon is increased, as for example RA.

Methods: Positive CCP RA patients (n=126) were tested prior to initiating biologic therapy with QFT-G TB (Cellestis). TB evaluation at baseline and annually for two years included history, physical, standard blood tests, chest radiograph, PPD and control skin testing.  RA patients had CCP, RF, Wesr, CRP, DAS, wrist temperature, tender and swollen joint counts at baseline (table 1).     Three healthy middle-aged female controls with no arthritis were tested with QFT-G TB.  Their serum was later tested with BiP added, with 2 ug/ml, 5ug/ml, 10ug/ml, and 20ug/ml, levels seen in RA. (Sourced BiP Novus Biologicals.)

Results: Of 126 CCP+ patients, 16 tested positive for TB (13%) by QFT-G TB, despite no known risk factors for TB (no travel, low endemic rural area, no exposure history), negative chest radiograph, negative PPD with positive candida control, normal blood testing, no symptoms or signs of TB. The CDC established local TB rate is 0.0007%. All 16 had high levels of CCP and active inflammation (mean DAS-esr 6.17). With consultation of an Infectious Disease specialist, all 16 patients received biologic therapy with no INH prophylaxis.  In follow up after 24 months, none developed TB and QFT-G TB reverted to negative in 5 patients, correlating with the RA control on biologic therapy. (The other 11 did not have repeat QFT-G.)  Mean QFT-G interferon levels in test tubes were 1.57 IU for TB, 0.18 IU for nil, and >10 IU for the mitogen tube.  Positive TB defined by the lab kit was > 0.35 IU. False TB interferon levels correlated with CCP level (p<0.02).    Three healthy women with no arthritis or TB exposure had negative QFT-G TB.  These three subjects tested positive every time for TB correlating to the dose of BiP added, at concentrations of 2 ug/ml, 5 ug/ml, 10 ug/ml, and 20 ug/ml (fig 1).

Conclusion: BiP is naturally found in the majority of  CCP+RA patients and presence of BiP in serum can result in a false positive QFT-G TB. Patients with the highest CCP had the highest QFT-G TB interferon levels.  Subsequent undertreatment of RA, if biologic therapy is withheld, and overtreatment of presumed latent TB may harm patients. 1.     Arth Rheum 2015;67:1171-1181.

2.     Arth Care Res 2015 Dec 1, on line.


Disclosure: J. Ball, None; K. Greenwald, None; A. A. Deodhar, AbbVie, 2,AbbVie, 9,Amgen, 2,Amgen, 9,Boehringer Ingelheim, 2,Boehringer Ingelheim, 9,Janssen Pharmaceutica Product, L.P., 2,Janssen Pharmaceutica Product, L.P., 9,Novartis Pharmaceutical Corporation, 2,Novartis Pharmaceutical Corporation, 9,Pfizer Inc, 2,Pfizer Inc, 9,UCB, 2,UCB, 9; K. L. Winthrop, None.

To cite this abstract in AMA style:

Ball J, Greenwald K, Deodhar AA, Winthrop KL. Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/immunoglobulin-binding-protein-bip-an-antigen-for-ccp-sero-positive-rheumatoid-arthritis-patients-can-result-in-a-false-positive-quantiferon-gold-tuberculosis-test/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunoglobulin-binding-protein-bip-an-antigen-for-ccp-sero-positive-rheumatoid-arthritis-patients-can-result-in-a-false-positive-quantiferon-gold-tuberculosis-test/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology